GM-CSF cancer vaccine (Thomas Jefferson/NCI)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGM-CSF cancer vaccine (Thomas Jefferson/NCI)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulants
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsUveal melanomaSolid tumoursLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSidney Kimmel Cancer Center At Thomas Jefferson UniversityWiseman Research Initiatives LlcNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsUveal melanomaSolid tumoursLiver Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A